Moderna and Merck are overvalued despite positive melanoma vaccine trial results

Youtube

·

Original Report

↗ Youtube

Traders are placing bearish bets on both Moderna and Merck, with significant put option activity, because they believe the stocks moved too far too fast following positive phase three trial results for Moderna's melanoma vaccine, and the initial data release lacked crucial details like hazard ratios and survival curves.